- Home
- MIRM vs SKYH Comparison
MIRM vs SKYH Comparison
Compare MIRM & SKYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- SKYH
- Stock Information
- Founded
- MIRM 2018
- SKYH 2017
- Country
- MIRM United States
- SKYH United States
- Employees
- MIRM N/A
- SKYH N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- SKYH Military/Government/Technical
- Sector
- MIRM Health Care
- SKYH Industrials
- Exchange
- MIRM Nasdaq
- SKYH Nasdaq
- Market Cap
- MIRM 1.9B
- SKYH N/A
- IPO Year
- MIRM 2019
- SKYH N/A
- Fundamental
- Price
- MIRM $44.27
- SKYH $11.65
- Analyst Decision
- MIRM Strong Buy
- SKYH Strong Buy
- Analyst Count
- MIRM 10
- SKYH 2
- Target Price
- MIRM $60.80
- SKYH $15.25
- AVG Volume (30 Days)
- MIRM 425.9K
- SKYH 101.3K
- Earning Date
- MIRM 05-07-2025
- SKYH 05-13-2025
- Dividend Yield
- MIRM N/A
- SKYH N/A
- EPS Growth
- MIRM N/A
- SKYH N/A
- EPS
- MIRM N/A
- SKYH N/A
- Revenue
- MIRM $379,251,000.00
- SKYH $14,761,000.00
- Revenue This Year
- MIRM $29.51
- SKYH $122.85
- Revenue Next Year
- MIRM $20.27
- SKYH $61.16
- P/E Ratio
- MIRM N/A
- SKYH N/A
- Revenue Growth
- MIRM 69.31
- SKYH 94.86
- 52 Week Low
- MIRM $23.83
- SKYH $8.26
- 52 Week High
- MIRM $54.23
- SKYH $14.52
- Technical
- Relative Strength Index (RSI)
- MIRM 56.45
- SKYH 56.09
- Support Level
- MIRM $40.00
- SKYH $10.88
- Resistance Level
- MIRM $47.43
- SKYH $11.43
- Average True Range (ATR)
- MIRM 2.07
- SKYH 0.41
- MACD
- MIRM 0.54
- SKYH 0.07
- Stochastic Oscillator
- MIRM 65.27
- SKYH 57.69
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.